Kansai Medical University Hirakata Hospital

Hirakata-shi, Osaka 573-1191

0 studies enrolling now · 1 studies all time

What they study most

ALK-positive Advanced NSCLC

Studies at this site

• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed